Reliance Secures Indian Patent

Strand Life Sciences, a subsidiary of Reliance Industries Limited, has announced the grant of an Indian patent for its AI-enabled blood test technology.
The technology is designed for early cancer detection and has the potential to revolutionize the healthcare industry.
- The patent grant is a significant milestone for the company, recognizing its innovative approach to healthcare technology.
- The AI-enabled blood test technology is expected to provide accurate and timely diagnosis, enabling early intervention and treatment.
The grant of this patent is a major achievement for Strand Life Sciences and is expected to have a significant impact on the healthcare industry.